Literature DB >> 20420492

Current therapeutic targets for the treatment of Alzheimer's disease.

Joshua D Grill1, Jeffrey L Cummings.   

Abstract

Alzheimer's disease is a progressive neurodegenerative disease for which no cure exists. There is a substantial need for new therapies that offer improved symptomatic benefit and disease-slowing capabilities. In recent decades there has been substantial progress in understanding the molecular and cellular changes associated with Alzheimer's disease pathology. This has resulted in identification of a large number of new drug targets. These targets include, but are not limited to, therapies that aim to prevent production of or remove the amyloid-beta protein that accumulates in neuritic plaques; to prevent the hyperphosphorylation and aggregation into paired helical filaments of the microtubule-associated protein tau; and to keep neurons alive and functioning normally in the face of these pathologic challenges. We provide a review of these targets for drug development.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20420492      PMCID: PMC4140224          DOI: 10.1586/ern.10.29

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  286 in total

1.  Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease.

Authors:  G Li; E B Larson; J A Sonnen; J B Shofer; E C Petrie; A Schantz; E R Peskind; M A Raskind; J C S Breitner; T J Montine
Journal:  Neurology       Date:  2007-08-28       Impact factor: 9.910

2.  Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies.

Authors:  A I Levey; C A Kitt; W F Simonds; D L Price; M R Brann
Journal:  J Neurosci       Date:  1991-10       Impact factor: 6.167

3.  Reduced protein phosphatase 2A activity induces hyperphosphorylation and altered compartmentalization of tau in transgenic mice.

Authors:  S Kins; A Crameri; D R Evans; B A Hemmings; R M Nitsch; J Gotz
Journal:  J Biol Chem       Date:  2001-07-25       Impact factor: 5.157

4.  Somatostatin regulates brain amyloid beta peptide Abeta42 through modulation of proteolytic degradation.

Authors:  Takashi Saito; Nobuhisa Iwata; Satoshi Tsubuki; Yoshie Takaki; Jiro Takano; Shu-Ming Huang; Takahiro Suemoto; Makoto Higuchi; Takaomi C Saido
Journal:  Nat Med       Date:  2005-03-20       Impact factor: 53.440

5.  Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation.

Authors:  Donna M Wilcock; Giovanni DiCarlo; Debbi Henderson; Jennifer Jackson; Keisha Clarke; Kenneth E Ugen; Marcia N Gordon; Dave Morgan
Journal:  J Neurosci       Date:  2003-05-01       Impact factor: 6.167

6.  Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease.

Authors:  M Eriksdotter Jönhagen; A Nordberg; K Amberla; L Bäckman; T Ebendal; B Meyerson; L Olson; M Shigeta; E Theodorsson; M Viitanen; B Winblad; L O Wahlund
Journal:  Dement Geriatr Cogn Disord       Date:  1998 Sep-Oct       Impact factor: 2.959

7.  Increase of BDNF serum concentration in lithium treated patients with early Alzheimer's disease.

Authors:  Thomas Leyhe; Gerhard W Eschweiler; Elke Stransky; Thomas Gasser; Peter Annas; Hans Basun; Christoph Laske
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

8.  Up-regulation of hippocampal serotonin metabolism in mild cognitive impairment.

Authors:  L Truchot; S N Costes; L Zimmer; B Laurent; D Le Bars; C Thomas-Antérion; B Croisile; B Mercier; M Hermier; A Vighetto; P Krolak-Salmon
Journal:  Neurology       Date:  2007-09-04       Impact factor: 9.910

9.  Microtubule-dependent oligomerization of tau. Implications for physiological tau function and tauopathies.

Authors:  Victoria Makrides; Ting E Shen; Rajinder Bhatia; Bettye L Smith; Julian Thimm; Ratneshwar Lal; Stuart C Feinstein
Journal:  J Biol Chem       Date:  2003-06-12       Impact factor: 5.157

10.  Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models.

Authors:  Irene H Cheng; Kimberly Scearce-Levie; Justin Legleiter; Jorge J Palop; Hilary Gerstein; Nga Bien-Ly; Jukka Puoliväli; Sylvain Lesné; Karen H Ashe; Paul J Muchowski; Lennart Mucke
Journal:  J Biol Chem       Date:  2007-06-04       Impact factor: 5.157

View more
  26 in total

Review 1.  Quantitative structural MRI for early detection of Alzheimer's disease.

Authors:  Linda K McEvoy; James B Brewer
Journal:  Expert Rev Neurother       Date:  2010-11       Impact factor: 4.618

2.  Brain transit and ameliorative effects of intranasally delivered anti-amyloid-β oligomer antibody in 5XFAD mice.

Authors:  Chun Xiao; Francesca J Davis; Balwantsinh C Chauhan; Kirsten L Viola; Pascale N Lacor; Pauline T Velasco; William L Klein; Neelima B Chauhan
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

Review 3.  Immunotherapy for Alzheimer's disease.

Authors:  Thomas Wisniewski; Fernando Goñi
Journal:  Biochem Pharmacol       Date:  2014-01-09       Impact factor: 5.858

4.  Site-specific inhibitory mechanism for amyloid β42 aggregation by catechol-type flavonoids targeting the Lys residues.

Authors:  Mizuho Sato; Kazuma Murakami; Mayumi Uno; Yu Nakagawa; Sumie Katayama; Ken-ichi Akagi; Yuichi Masuda; Kiyonori Takegoshi; Kazuhiro Irie
Journal:  J Biol Chem       Date:  2013-06-21       Impact factor: 5.157

5.  Electromagnetic radiation 2450 MHz exposure causes cognition deficit with mitochondrial dysfunction and activation of intrinsic pathway of apoptosis in rats.

Authors:  Sukesh Kumar Gupta; Manoj Kumar Mesharam; Sairam Krishnamurthy
Journal:  J Biosci       Date:  2018-06       Impact factor: 1.826

Review 6.  Disrupting self-assembly and toxicity of amyloidogenic protein oligomers by "molecular tweezers" - from the test tube to animal models.

Authors:  Aida Attar; Gal Bitan
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

7.  Novel immunological approaches for the treatment of Alzheimer's disease.

Authors:  Priyanka Sabharwal; Thomas Wisniewski
Journal:  Zhongguo Xian Dai Shen Jing Ji Bing Za Zhi       Date:  2014

Review 8.  Mechanisms of action of amyloid-beta and its precursor protein in neuronal cell death.

Authors:  Yong Qi Leong; Khuen Yen Ng; Soi Moi Chye; Anna Pick Kiong Ling; Rhun Yian Koh
Journal:  Metab Brain Dis       Date:  2019-12-06       Impact factor: 3.584

9.  NSAID-based γ-secretase modulators do not bind to the amyloid-β polypeptide.

Authors:  Paul J Barrett; Charles R Sanders; Stephen A Kaufman; Klaus Michelsen; John B Jordan
Journal:  Biochemistry       Date:  2011-11-02       Impact factor: 3.162

10.  Muscle-directed anti-Aβ single-chain antibody delivery via AAV1 reduces cerebral Aβ load in an Alzheimer's disease mouse model.

Authors:  Junling Yang; Abhinandan Pattanayak; Min Song; Jinghong Kou; Hiroaki Taguchi; Sudhir Paul; Selvarangan Ponnazhagan; Robert Lalonde; Ken-ichiro Fukuchi
Journal:  J Mol Neurosci       Date:  2012-09-04       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.